查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856700

血管栓塞市場按產品類型、應用和最終用戶分類－2025年至2032年全球預測

Vascular Embolization Market by Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血管栓塞市場規模將達到 56.6 億美元，複合年成長率為 11.76%。

關鍵市場統計數據
基準年 2024 23.2億美元
預計年份：2025年 25.9億美元
預測年份 2032 56.6億美元
複合年成長率 (%) 11.76%

血管栓塞術簡介：臨床促進因素、器械發展和手術整合正在塑造現代醫療保健服務。

血管栓塞術已從一項小眾介入手術發展成為微創治療多種血管和腫瘤疾病的基石。現代實踐將設備創新與先進的影像引導技術相結合，能夠比以往任何一代手術更精準、更安全地治療動靜脈畸形、腫瘤出血、子宮肌瘤和創傷性出血等疾病。本文概述了推動血管栓塞術在各種臨床環境中廣泛應用的臨床促進因素、技術進步和手術發展趨勢。

導管技術和栓塞劑化學的快速發展正在重塑手術流程。操控性較佳、直徑較小的微導管能夠到達遠端解剖結構，而從可脫卸彈簧圈到校準微球和液體栓塞劑等各種改良的栓塞劑，為外科醫生提供了多種針對病變生理特徵的栓塞選擇。同時，術中影像技術的進步，包括錐狀射束CT和融合導航，提高了病灶定位的準確性，並降低了非標靶栓塞的風險。這些進步對培訓、器材採購和介入團隊組成都產生了影響。

臨床醫生也積極應對患者期望的改變以及縮短住院時間和降低手術風險的系統性要求。因此，栓塞術正日益融入多學科診療路徑，包括放射科、血管外科、腫瘤科和婦科。本節概述了栓塞術的臨床原理、器械和技術演變以及操作環境，為後續更深入的分析奠定了基礎，展現了栓塞術的不斷成熟。

透過小型化、先進的影像技術以及整合的臨床和商業模式，栓塞療法正經歷一場變革性的轉變，並被重新定義。

栓塞治療領域正在經歷多方面的變革，涵蓋臨床實踐、產品設計和商業策略。器械小型化和輸送能力的提升使得以往難以觸及的部位得以進入，從而拓展了治療的可能性。同時，栓塞劑也朝著可預測、可調控的閉塞方向發展，液體製劑則能像模具一樣滲透到複雜的血管床。這些進步共同改變了許多適應症的風險獲益比，並迫使臨床醫生重新審視治療流程。

影像保真度和手術規劃的改進，以及材料和導管的創新，正在加速以主導為導向的決策。即時影像和術後檢驗工具降低了不確定性，並支持符合條件的患者當日出院，這反過來又影響了醫院的運作效率和服務線的經濟效益。此外，混合手術的興起，即結合栓塞術和消融術、標靶全身性治療等輔助療法，正在催生新的跨學科臨床通訊協定。

在商業性，製造商正透過整合設備、培訓和療效支援等提案，提供綜合價值主張來因應市場變化。上市後監管和強調臨床證據的法規正推動產品研發朝著可驗證的安全性和長期療效方向發展。相關人員應預期，基於價值的合約和臨床療效比較證據將在採購決策中發揮日益重要的作用，尤其是在醫療系統尋求能夠提供穩定手術效果和可衡量後續獲益的療法時。

評估美國關稅到2025年對供應鏈採購和臨床採購動態的累積營運和策略影響

貿易政策發展和2025年前的關稅措施正對栓塞治療供應鏈的營運動態、籌資策略和臨床應用產生多方面的影響。關稅主導的成本壓力促使醫療服務提供者和製造商重新評估其採購佈局，並專注於地理多元化和嚴格的庫存管理。製造商則透過考慮本地生產能力、區域分銷中心和戰略供應商協議來降低跨境貿易波動帶來的風險。

從臨床角度來看，關稅的間接影響將反映在採購優先順序的調整上。醫療系統，尤其是那些預算緊張的系統，可能會推遲擇期手術，或轉向採購落地成本較低的器械和耗材，這可能會影響新型器械和先進栓塞劑的引進時間。同時，由於臨床團隊優先考慮器械的可靠性和手術效果，關稅帶來的持續成本影響可能會導致與供應商曠日持久的談判，以及為了平衡價格和臨床效果而達成的附加條件採購協議。

從創新角度來看，製造商面臨著在保護研發投資和管理生產經濟效益之間尋求平衡的難題。如果製造商發現短期收入存在不確定性，關稅導致的成本波動可能會延緩小眾或高複雜度產品的商業化。另一方面，對供應鏈韌性的需求促使製造商投資於替代製造地和策略聯盟，以實現關鍵零件的在地化生產。總體而言，關稅動態凸顯了供應鏈透明度、合約靈活性以及製造商、經銷商和臨床相關人員之間密切合作的戰略重要性，以確保能夠獲得全方位的栓塞技術。

細分市場層面的洞察揭示了產品類型使用情況和最終用戶動態如何影響臨床應用的採購和策略優先排序。

對細分市場的詳細分析闡明了臨床需求、創新重點和採購決策的交匯點。依產品類型分類，器械分為附件、導管和栓塞劑。配件包括導管導引線、鞘套和注射器，這些配件有助於提高手術效率和安全性。導管分為大導管和微導管，二者的設計重點各不相同。大導管包括球囊導管和診斷導管，這些導管便於近端血管通路建立和血流控制。微導管則分為血流導引型微導管和附導線針對遠端導航和標靶輸送進行了最佳化。栓塞劑涵蓋了廣泛的化學成分，包括可脫卸和可推送的栓塞彈簧圈；液態栓塞劑，例如乙烯 - 乙烯醇和N-丁基氰基丙烯酸酯；以及提供校準或非校準頻譜的微球，用於實現可預測的血管閉塞。以及用於暫時或永久性血管阻塞的顆粒劑，例如明膠海綿顆粒和聚乙烯醇顆粒。

針對特定應用場景的細分有助於明確臨床應用案例，並為設備選擇和培訓需求提供基礎。栓塞手術包括動靜脈畸形（包括腦、周邊和脊髓區域的亞型）；主要用於治療咯血的支氣管栓塞；腫瘤介入治療，例如肝癌栓塞，以及需要快速肺動脈栓塞的消化道出血情況；肺栓塞（區分急性與慢性血栓栓塞性肺動脈高壓）；創傷性出血管理；以及子宮肌瘤治療（其中保留生育功能至關重要）。每種應用場景都對設備性能有特定的要求，並且對藥物的持久性、控制和影像清晰度也有不同的預期。

門診手術中心、醫院和專科診所的手術量、人員配備模式和資金限制各不相同。門診手術中心著重手術效率和當日復健通訊協定，醫院則需平衡急診和擇期手術的需求，而專科診所通常集中手術專長，並作為特定適應症的卓越中心。了解產品類型、應用和最終使用者之間的相互關係，對於協調臨床教育、供應鏈和商業性推廣，從而與相關人員做出適當的決策至關重要。

地理因素影響美洲、歐洲、中東和非洲以及亞太地區招聘法規和基礎設施的差異

區域動態對技術採納軌跡、報銷機制以及專業臨床人才的可近性有顯著影響。在美洲，成熟的介入放射學基礎設施體現在其臨床實踐模式中，先進的影像技術和設備平台得到了廣泛應用。這種環境有利於快速採用能夠提高手術效率和患者吞吐量的設備，同時，不斷發展的報銷機制和基於價值的醫療服務模式也促使醫療機構在臨床和經濟效益方面取得切實可見的進步。

區域差異正在影響歐洲、中東和非洲的醫療服務取得和採購。歐洲一些資源豐富的中心正在引領新型栓塞劑和複雜手術組合的應用，而該地區的其他國家則優先考慮成本效益和供應的連續性。中東新興的醫療中心正集中投資於三級醫療中心，而一些非洲國家則透過培訓夥伴關係和有針對性的基礎設施升級來提升醫療能力。這些不同的動態意味著，製造商和臨床領導者必須使其實證醫學研究和打入市場策略與次區域支付方的期望和採購慣例相適應。

亞太地區正經歷快速的產能擴張，並高度重視與當地相關的臨床數據和培訓計畫。手術量的增加、介入性心臟病學和放射學從業人員的擴充以及影像基礎設施的投資，正在加速各種適應症的推廣應用。然而，供應鏈的考量以及不同司法管轄區的監管差異，要求採取一種精細化的商業化策略，既要兼顧集中化的監管核准，又要兼顧針對特定國家的價值論證和臨床醫生教育工作。

老牌製造商與專業創新者之間的競爭行為：創新路徑和合作策略塑造臨床和商業競爭

栓塞領域的競爭動態取決於產品系列的廣度、臨床證據的累積以及提供能夠降低手術複雜性的整合解決方案的能力。成熟的醫療設備製造商利用其全球分銷網路和監管經驗來擴大新型導管設計和栓塞劑的規模，而新興的專業公司則透過專注於新型材料和平台技術的投資來推動創新。在這種由現有企業和利基創新者並存的競爭環境中，夥伴關係、授權協議和定向收購已成為加速產品臨床應用的常見機制。

製造商越來越重視產品獨立功能以外的差異化價值提案，包括臨床醫生培訓、手術支援和數據主導的結果監測。參與真實世界證據計畫和註冊研究能夠增強臨床可信度，而與學術中心的合作則有助於改善設備適配和最佳實踐技術。與經銷商和醫院集團採購組織的供應關係會影響通路動態，能夠提供供應保障、透明定價模式和上市後監測支援的公司往往更容易獲得採購合作夥伴的配合。

創新軌跡也體現了對輔助技術的推動，例如增強影像處理、更可控的栓塞輸送系統以及將栓塞與生物活性或靶向有效載荷相結合的新一代藥物。隨著支付方和相關人員要求證明患者獲益，能夠高效產生可靠的臨床結果數據並將產品開發與相關人員需求相結合的公司，將在這個不斷變化的環境中佔據有利地位，保持競爭優勢。

為產業領導者提供切實可行的策略建議，以增強供應鏈韌性、加速產品應用，並使採購重點與臨床價值保持一致。

產業領導者應優先考慮一系列切實可行的策略，以最大限度地提高栓塞治療的臨床療效和商業性韌性。首先，應投資於供應鏈的透明度和多元化，以降低跨境貿易中斷和關稅波動帶來的風險。本地庫存和關鍵部件的多元化採購將有助於增強營運連續性，並支援對臨床需求的快速反應。

其次，我們將透過深化與高流量中心和多學科團隊的夥伴關係，開發符合臨床醫師主導應用情境的產品。我們將共同製定操作規程和訓練課程，確保結果可重複，並縮短先進設備的學習曲線。這種方法將有助於提高臨床醫生的認可度，並加速在各種終端使用者環境中安全應用。

第三，將證據產生計畫納入您的商業化時間表。完善的臨床註冊研究和能夠捕捉功能性結果、併發症發生率和資源利用情況的實用性真實世界研究，將有助於您與支付方和醫院採購委員會展開討論。重點關注對臨床醫生和管理者都至關重要的結果，例如縮短住院時間和減少再次手術的需求。

最後，考慮將設備、培訓和結果支援相結合的捆綁式價值提案，以在競爭激烈的採購環境中脫穎而出。儘早與臨床和採購相關人員接洽，共同製定服務水準協議和售後支援模式，將有助於加強長期夥伴關係，並根據現場回饋不斷改進產品。

一份可重複且透明的調查方法，概述了支持報告結論的主要研究、文獻綜述、分析方法和檢驗步驟。

本研究整合了主要相關人員訪談、同行評審的臨床文獻、監管文件、手術操作指南和器械標籤訊息，建構了一個可重複的分析基礎。主要資料來源包括對各專科介入臨床醫生、門診手術中心和醫院的採購負責人以及產品開發主管進行的結構化訪談，以了解不同地區的手術偏好、預期器械性能和採購考慮。次要分析則依賴已發表的臨床研究、共識聲明和器械性能報告，以驗證臨床醫生的意見與已記錄的安全性和有效性結果。

分析方法包括對訪談記錄進行定性主題編碼和比較設備功能映射，以識別反覆出現的臨床需求和設計權衡。區域採用趨勢分析依賴公立醫院登記處報告的手術量趨勢以及專業協會指南（如有）。供應鏈評估結合了供應商資訊和公開的貿易及監管數據，以評估潛在的風險點。檢驗步驟包括將臨床醫師報告的實務模式與手術層面的證據進行交叉比對，並邀請資深介入專家進行專家評審，以確保臨床有效性。

此方法強調透明度，關鍵假設、納入標準以及主要和次要來源均記錄在技術附錄中。這種結構便於讀者復現分析步驟、查閱資料，並根據自身機構的具體問題或後續研究活動調整框架。

簡明扼要的結論總結了技術、臨床和操作方面的優先事項，旨在指南栓塞治療相關相關人員的策略決策。

結論綜合了臨床需求、器械創新和操作限制相互作用所湧現的核心主題。栓塞術已進入一個階段，漸進式設計改進和新型栓塞劑大大擴展了治療手段，使臨床醫生能夠更有信心地治療更複雜的解剖結構。同時，影像學和手術相關訓練的進步正在縮短學習曲線，提高安全性，並加強栓塞術在多學科診療路徑中的作用。

在營運層面，供應鏈韌性和基於證據的價值論證將決定技術應用的速度和模式。積極追求採購透明度、降低區域供應風險並產生以結果為導向的證據的製造商和醫療服務提供者，將更有能力應對多樣化的醫療環境。關稅相關的壓力以及報銷和基礎設施方面的區域差異，將要求制定適應性策略，以平衡短期成本控制與對臨床檢驗和臨床醫生參與的長期投資。

最終，該領域的發展趨勢傾向於將設備性能、手術支援和可證實的臨床價值相結合的整合解決方案。將產品開發與臨床醫生的工作流程相協調、優先考慮高品質證據並保持靈活的商業和生產模式的相關人員，將創造永續的競爭優勢並改善患者的治療效果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 用於標靶化療栓塞治療的可生物分解微球的擴展。
  • 整合先進的影像導引系統以提高栓塞術的準確性
  • 液體栓塞劑在治療周邊動脈阻塞的應用日益廣泛
  • 開發用於增強手術過程中透視可見性的滲透性
  • 3D血管模型在血管栓塞術前規劃與訓練的應用日益廣泛
  • 人工智慧驅動的栓塞劑選擇和手術結果預測軟體的出現

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的血管栓塞市場

  • 配件
    • 導管導引線
    • 鞘套
    • 注射器
  • 導管
    • 大導管
      • 球囊導管
      • 診斷導管
    • 微導管
      • 直流式微導管
      • 附導線式微導管
  • 栓塞劑
    • 栓塞線圈
      • 可拆卸線圈
      • 可推式線圈
    • 液態栓塞劑
      • 乙烯 - 乙烯醇共聚物
      • N-丁基氰基丙烯酸酯
    • 微球
      • 校準微球
      • 未校準的微球
    • 顆粒栓塞劑
      • 明膠海綿顆粒
      • 聚乙烯醇顆粒

9. 按應用分類的血管栓塞市場

  • 動靜脈畸形
    • 腦動靜脈畸形
    • 周邊動靜脈畸形
    • 脊髓動靜脈畸形
  • 支氣管栓塞
    • 咯血管理
  • 消化道出血
  • 肝癌
  • 肺栓塞
    • 急性肺動脈栓塞
    • 慢性血栓栓塞性肺動脈高壓
  • 創傷管理
  • 子宮肌瘤

第10章 依最終用戶分類的血管栓塞市場

  • 門診手術中心
  • 醫院
  • 專科診所

第11章 區域血管栓塞市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 血管栓塞市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國血管栓塞市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Terumo Corporation
    • Boston Scientific Corporation
    • Medtronic plc
    • Johnson & Johnson
    • Stryker Corporation
    • Merit Medical Systems, Inc.
    • Cook Medical LLC
    • Penumbra, Inc.
    • B. Braun Melsungen AG
    • Becton Dickinson and Company
Product Code: MRR-742BD5184D4D

The Vascular Embolization Market is projected to grow by USD 5.66 billion at a CAGR of 11.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.32 billion
Estimated Year [2025] USD 2.59 billion
Forecast Year [2032] USD 5.66 billion
CAGR (%) 11.76%

Foundational introduction to vascular embolization delineating clinical drivers, device evolution, and procedural integration shaping contemporary care delivery

Vascular embolization has evolved from a niche interventional procedure into a cornerstone of minimally invasive therapy for a wide range of vascular and oncologic conditions. Contemporary practice blends device innovation with advanced image guidance, enabling clinicians to treat arteriovenous malformations, oncologic bleeding, uterine fibroids, and traumatic hemorrhage with greater precision and safety than earlier generations of techniques. This introduction frames the clinical drivers, technological enablers, and procedural trends that are accelerating adoption across diverse care settings.

Rapid progress in catheter technology and embolic agent chemistry is redefining procedural workflows. Improved navigability and smaller profile microcatheters allow access to distal anatomy, while refined embolic agents-from detachable coils to calibrated microspheres and liquid agents-provide operators with a broader spectrum of occlusion options tailored to lesion physiology. Concurrent advances in intraprocedural imaging, including cone beam CT and fusion-based navigation, increase lesion localization accuracy and reduce non-target embolization risk. These developments have implications for training, procurement, and interventional team composition.

Clinicians are also responding to changing patient expectations and system-level imperatives to shorten hospital stays and reduce procedural risk. As such, embolization is increasingly integrated into multidisciplinary care pathways involving radiology, vascular surgery, oncology, and gynecology. This section sets the stage for deeper analysis by outlining the clinical rationale, device and procedural evolution, and the operational context in which embolization continues to mature.

Transformative shifts redefining embolization therapy driven by device miniaturization, imaging precision, and integrated clinical and commercial models

The landscape of embolization is undergoing several transformative shifts that touch clinical practice, product design, and commercial strategy. Device miniaturization paired with enhanced deliverability is enabling access to previously untreatable anatomies and expanding the therapeutic envelope. This technical evolution is complemented by a move toward embolic agents that provide predictable, calibrated occlusion and by liquid formulations that offer cast-like penetration for complex vascular beds. Together, these advances are shifting the risk-benefit calculus for many indications and prompting clinicians to revisit treatment algorithms.

Parallel to material and catheter innovation, improvements in imaging fidelity and procedural planning are accelerating procedurally driven decision-making. Real-time imaging and post-deployment verification tools reduce uncertainty and support same-day discharge pathways in appropriate patients, which in turn influences hospital throughput and service line economics. Moreover, the rise of hybrid procedures that combine embolization with adjunctive therapies, such as ablation or targeted systemic treatment, is creating new interdisciplinary clinical protocols.

Commercially, manufacturers are responding with integrated value propositions that bundle devices, training, and outcomes support. Regulatory emphasis on post-market surveillance and clinical evidence is steering product development toward demonstrable safety and long-term performance. Stakeholders should anticipate that value-based contracting and evidence of comparative clinical effectiveness will play an increasingly prominent role in procurement decisions, especially as health systems seek therapies that deliver consistent procedural outcomes with measurable downstream benefits.

Assessment of cumulative operational and strategic impacts from United States tariff measures through 2025 on supply chains sourcing and clinical procurement dynamics

Trade policy developments and tariff measures introduced through 2025 have had a multifaceted influence on the operational dynamics of embolization supply chains, procurement strategies, and clinical access. Tariff-driven cost pressures have prompted healthcare providers and manufacturers to reassess sourcing footprints, with an emphasis on geographic diversification and closer inventory management. Manufacturers have responded by examining localized production capacity, regional distribution hubs, and strategic supplier contracts to mitigate exposure to cross-border trade variability.

Clinically, the indirect effects of tariffs manifest through procurement prioritization. Health systems, particularly those operating under tight budgetary constraints, may defer elective procedures or shift toward devices and consumables with lower landed costs, which can influence the adoption timing of newer device classes and advanced embolic agents. At the same time, clinical teams prioritize device reliability and procedural performance, so sustained tariff-related cost implications can lead to longer-term supplier negotiations and conditional purchasing arrangements that balance price with clinical outcomes.

From an innovation perspective, manufacturers face a balancing act between safeguarding R&D investment and managing production economics. Tariff-induced cost volatility can slow the commercialization timeline for niche or high-complexity products if manufacturers deem near-term returns uncertain. Conversely, the need for supply chain resilience has spurred investments in alternate manufacturing sites and in strategic partnerships that localize critical component production. Overall, tariff dynamics reinforce the strategic importance of supply chain transparency, contractual flexibility, and close collaboration among manufacturers, distributors, and clinical stakeholders to preserve access to the full range of embolization technologies.

Segment-level insights clarifying how product type application and end-user dynamics influence clinical adoption procurement and strategic prioritization

A granular view of segmentation clarifies where clinical demand, innovation focus, and purchasing decision-making converge. Across product types, devices are categorized into accessories, catheters, and embolic agents; accessories encompass guide wires, sheaths, and syringes that support procedural efficiency and safety, while catheters divide into macrocatheters and microcatheters, each with distinct design priorities. Macrocatheters include balloon catheters and diagnostic catheters that facilitate proximal vessel access and flow control, whereas microcatheters split into flow-directed microcatheters and over-the-wire microcatheters optimized for distal navigation and targeted delivery. Embolic agents represent a broad chemistry spectrum, including embolic coils that are available as detachable or pushable variants, liquid embolic agents such as ethylene vinyl alcohol copolymer and N-butyl cyanoacrylate that provide cast-like penetration, microspheres offered as calibrated or non-calibrated formulations for predictable occlusion, and particulate agents including gelatin sponge particles and polyvinyl alcohol particles used for temporary or permanent vessel occlusion.

Application-focused segmentation delineates clinical use cases and informs device selection and training needs. Embolization procedures address arteriovenous malformations with subtypes in brain, peripheral, and spinal territories, bronchial embolization primarily targeting hemoptysis management, gastrointestinal bleeding scenarios where rapid hemostasis is critical, oncologic interventions such as liver cancer embolotherapy, pulmonary embolization that differentiates acute pulmonary embolism from chronic thromboembolic pulmonary hypertension, trauma-focused hemorrhage control, and uterine fibroid management where fertility-preserving options matter. Each application imposes particular device performance requirements and varying expectations for agent permanence, control, and imaging visibility.

End-user segmentation affects procurement timelines and adoption curves, with ambulatory surgical centers, hospitals, and specialty clinics each presenting different procedural volumes, staffing models, and capital constraints. Ambulatory surgical centers emphasize throughput and same-day recovery protocols, hospitals balance acute and elective demand across higher acuity cases, and specialty clinics often concentrate procedural expertise and serve as centers of excellence for defined indications. Understanding the interplay among product type, application, and end user is essential for aligning clinical education, supply arrangements, and commercial outreach to the right decision-making stakeholders.

Geographic dynamics shaping adoption regulatory and infrastructure distinctions across the Americas Europe Middle East & Africa and Asia-Pacific regions

Regional dynamics exert a powerful influence on technology adoption pathways, reimbursement frameworks, and the availability of specialized clinical expertise. In the Americas, practice patterns reflect a mature interventional radiology infrastructure with broad uptake of advanced imaging and device platforms, and care delivery models that increasingly emphasize outpatient pathways and bundled clinical programs. This environment supports rapid iteration of devices that enhance procedural efficiency and patient throughput, while reimbursement evolution and value-based care initiatives push providers to demonstrate tangible improvements in clinical and economic outcomes.

In Europe, Middle East & Africa, regional heterogeneity shapes access and procurement. High-resource centers in parts of Europe lead in adoption of novel embolic agents and complex procedural combinations, while other countries within the region prioritize cost-effectiveness and supply continuity. Emerging hubs in the Middle East concentrate investments in tertiary centers of excellence, and select countries in Africa are building capacity through training partnerships and targeted infrastructure upgrades. These diverse dynamics mean that manufacturers and clinical leaders must tailor evidence generation and market access strategies to subregional payer expectations and procurement practices.

The Asia-Pacific region presents rapid capacity expansion and a strong emphasis on locally relevant clinical data and training programs. Growing procedural volumes, expanding interventional cardiology and radiology workforces, and investments in imaging infrastructure are accelerating adoption across a range of indications. However, supply chain considerations and regulatory variability across jurisdictions require nuanced commercialization approaches that balance centralized regulatory approvals with country-specific value demonstration and clinician education efforts.

Competitive behavior innovation pathways and partnership strategies among established manufacturers and specialized innovators shaping clinical and commercial competition

Competitive dynamics in the embolization space are defined by product portfolio breadth, clinical evidence generation, and the ability to deliver integrated solutions that reduce procedural complexity. Established medical device companies leverage global distribution networks and regulatory experience to scale new catheter designs and embolic chemistries, while emerging specialized firms drive innovation through focused investments in novel materials and platform technologies. This mix of incumbents and niche innovators creates a competitive environment where partnerships, licensing arrangements, and targeted acquisitions are common mechanisms to accelerate time to clinical adoption.

Manufacturers are increasingly emphasizing differentiated value propositions that go beyond single-product features to include clinician training, procedural support, and data-driven outcomes monitoring. Real-world evidence programs and registry participation strengthen clinical credibility, and collaborations with academic centers help refine device indications and best-practice techniques. Supply relationships with distributors and hospital group purchasing organizations influence channel dynamics, and firms that can offer supply assurance, transparent pricing models, and post-market surveillance support tend to find more receptive procurement partners.

Innovation pathways also reflect a push toward adjunctive technologies such as imaging enhancements, embolic delivery systems with improved control, and next-generation agents that combine embolic occlusion with bioactive or targeted payloads. As payers and providers look for demonstrable patient benefits, the companies that can efficiently generate robust clinical outcomes data and align product development with stakeholder needs will maintain a competitive advantage in the evolving landscape.

Actionable strategic recommendations for industry leaders to strengthen supply resilience accelerate adoption and align clinical value with procurement priorities

Industry leaders should prioritize a set of actionable strategies to maximize clinical impact and commercial resilience in embolization therapy. First, invest in supply chain transparency and diversification to reduce exposure to cross-border trade disruptions and tariff fluctuations. Localized inventory hubs and multi-sourcing of critical components will enhance operational continuity and support rapid clinical demand responsiveness.

Second, align product development with clinician-driven use cases by deepening partnerships with high-volume centers and multidisciplinary teams. Co-develop procedural protocols and training curricula that demonstrate reproducible outcomes and shorten the learning curve for advanced devices. This approach fosters clinician advocacy and accelerates safe adoption across varied end-user settings.

Third, integrate evidence-generation plans into commercialization timelines. Robust clinical registries and pragmatic real-world studies that capture functional outcomes, complication rates, and resource utilization will facilitate discussions with payers and hospital procurement committees. Emphasize outcomes that matter to both clinicians and administrators, such as reduced hospital length of stay and decreased need for repeat procedures.

Finally, consider bundled value propositions that combine devices, education, and outcomes support to differentiate offerings in competitive procurement environments. Engaging early with clinical and procurement stakeholders to co-create service-level agreements and post-sale support models will strengthen long-term partnerships and create pathways for iterative product improvements based on frontline feedback.

Transparent reproducible research methodology outlining primary interviews literature review analytical frameworks and validation steps supporting the report findings

This research synthesizes primary stakeholder interviews, peer-reviewed clinical literature, regulatory filings, procedural practice guidelines, and device labeling information to produce a reproducible analytical foundation. Primary inputs included structured interviews with interventional clinicians across specialties, procurement leaders from ambulatory surgical centers and hospitals, and product development executives; these interviews were conducted to capture procedural preferences, device performance expectations, and procurement considerations across geographic regions. Secondary analysis relied on published clinical studies, consensus statements, and device performance reports to triangulate clinician perspectives with documented safety and efficacy outcomes.

Analytical methods incorporated qualitative thematic coding of interview transcripts and comparative device feature mapping to identify recurring clinical needs and design trade-offs. Regional adoption analyses were informed by procedural volume trends reported in public hospital registries and professional society guidance where available, while supply chain assessments combined supplier mapping with publicly available trade and regulatory data to evaluate potential exposure points. Validation steps included cross-referencing clinician-reported practice patterns with procedure-level evidence and soliciting expert review from senior interventional practitioners to ensure clinical plausibility.

The methodology emphasizes transparency: key assumptions, inclusion criteria, and the provenance of primary and secondary sources are documented in the technical appendix. This structure allows readers to replicate analytical steps, interrogate source material, and adapt the framework to institution-specific questions or follow-up research activities.

Concise conclusion synthesizing technological clinical and operational priorities that should guide strategic decision-making across embolization stakeholders

The conclusion synthesizes the core themes that emerge from the interplay of clinical needs, device innovation, and operational constraints. Embolization has entered a phase where incremental design improvements and novel embolic chemistries materially expand the therapeutic repertoire, enabling clinicians to treat more complex anatomies with greater confidence. Concurrently, imaging advances and procedure-focused training shorten learning curves and enhance safety, reinforcing embolization's role in multidisciplinary care pathways.

Operationally, supply chain resilience and evidence-based value demonstration will shape the pace and pattern of adoption. Manufacturers and providers that proactively address procurement transparency, localized supply risk mitigation, and outcomes-oriented evidence generation will be better positioned to serve diverse care settings. Tariff-related pressures and regional heterogeneity in reimbursement and infrastructure require adaptive strategies that balance near-term cost management with longer-term investments in clinical validation and clinician engagement.

Ultimately, the field's trajectory favors integrated solutions that combine device performance, procedural support, and demonstrable clinical value. Stakeholders who align product development with clinician workflows, prioritize high-quality evidence, and maintain flexible commercial and manufacturing models will create durable competitive advantages and improve patient-level outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of biodegradable microspheres for targeted chemoembolization therapies
  • 5.2. Integration of advanced imaging guidance systems to improve embolization accuracy
  • 5.3. Rising adoption of liquid embolic agents in peripheral arterial occlusion treatments
  • 5.4. Development of radiopaque microspheres enhancing fluoroscopic visibility during procedures
  • 5.5. Increasing use of three-dimensional printed vascular models for preprocedural embolization planning and training
  • 5.6. Emergence of AI-driven software for embolic agent selection and procedural outcome prediction

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Embolization Market, by Product Type

  • 8.1. Accessories
    • 8.1.1. Guide Wires
    • 8.1.2. Sheaths
    • 8.1.3. Syringes
  • 8.2. Catheters
    • 8.2.1. Macrocatheters
      • 8.2.1.1. Balloon Catheters
      • 8.2.1.2. Diagnostic Catheters
    • 8.2.2. Microcatheters
      • 8.2.2.1. Flow Directed Microcatheters
      • 8.2.2.2. Over The Wire Microcatheters
  • 8.3. Embolic Agents
    • 8.3.1. Embolic Coils
      • 8.3.1.1. Detachable Coils
      • 8.3.1.2. Pushable Coils
    • 8.3.2. Liquid Embolic Agents
      • 8.3.2.1. Ethylene Vinyl Alcohol Copolymer
      • 8.3.2.2. N-Butyl Cyanoacrylate
    • 8.3.3. Microspheres
      • 8.3.3.1. Calibrated Microspheres
      • 8.3.3.2. Non-Calibrated Microspheres
    • 8.3.4. Particulate Embolic Agents
      • 8.3.4.1. Gelatin Sponge Particles
      • 8.3.4.2. Polyvinyl Alcohol Particles

9. Vascular Embolization Market, by Application

  • 9.1. Arteriovenous Malformations
    • 9.1.1. Brain Arteriovenous Malformations
    • 9.1.2. Peripheral Arteriovenous Malformations
    • 9.1.3. Spinal Arteriovenous Malformations
  • 9.2. Bronchial Embolization
    • 9.2.1. Hemoptysis Management
  • 9.3. Gastrointestinal Bleeding
  • 9.4. Liver Cancer
  • 9.5. Pulmonary Embolization
    • 9.5.1. Acute Pulmonary Embolism
    • 9.5.2. Chronic Thromboembolic Pulmonary Hypertension
  • 9.6. Trauma Management
  • 9.7. Uterine Fibroids

10. Vascular Embolization Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Vascular Embolization Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Vascular Embolization Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Vascular Embolization Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Terumo Corporation
    • 14.3.2. Boston Scientific Corporation
    • 14.3.3. Medtronic plc
    • 14.3.4. Johnson & Johnson
    • 14.3.5. Stryker Corporation
    • 14.3.6. Merit Medical Systems, Inc.
    • 14.3.7. Cook Medical LLC
    • 14.3.8. Penumbra, Inc.
    • 14.3.9. B. Braun Melsungen AG
    • 14.3.10. Becton Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA VASCULAR EMBOLIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. VASCULAR EMBOLIZATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. VASCULAR EMBOLIZATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VASCULAR EMBOLIZATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, B